Uncategorized
Ocata Therapeutics Secures $10 Million in Debt Financing
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it has entered into a secured term loan facility of up to $10 million with Silicon Valley Bank. Ocata received initial funding of $6 million and has a conditional option to receive an additional $4 million upon the successful completion of certain clinical and corporate milestones. Ocata intends to use the proceeds for general corporate purpose
